• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Ophthalmology >Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients
【24h】

Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients

机译：降低纤维素甲氨蝶呤注射的频率降低了ViteoroRetinal淋巴瘤患者角病的风险

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Intravitreal methotrexate has been proven to be an effective treatment method for vitreoretinal lymphoma. However, keratopathy occurs as the major side effect during treatment in most cases. The purpose of this study is to describe the characteristics of primary central nervous system lymphoma (PCNSL) with intraocular involvement and to attempt to reduce the incidence of keratopathy caused by intravitreal methotrexate. The medical records of 22 PCNSL patients with intraocular involvement (33 eyes) were reviewed. Patients were divided into two groups. Group A (22 eyes) received the induction-consolidation-maintenance regimen, which consisted of intravitreal methotrexate injection at a dosage of 400?μg/0.1?ml twice a week for the first four weeks, weekly for the following eight weeks, and then monthly for the last nine months. Patients with a poor systemic condition were assigned to Group B (8 eyes), who were started on the treatment protocol described above and switched directly to monthly injection (9?months) when ocular remission was achieved. Blurred vision (31%) and floaters (25%) were common presenting symptoms. Vitritis was the most common clinical sign and was present in 29 eyes (90%) on B-ultrasound examination. Diagnosis was made by 25G-pars plana vitrectomy, and most diagnoses were diffuse large B-cell lymphoma. Ocular remission was achieved after 8.2 (SD?=?4.6) injections of methotrexate. The mean VA (visual acuity) was improved from LogMAR 0.65 to 0.3 (P?=?0.002). Keratopathy was observed in 21 eyes (66%) after an average of 8.2 (SD?=?2.3) injections. With a reduced injection frequency, the incidence of keratopathy was lowered from 86.4% (Group A) to 25.0% (Group B) without ocular recurrence during follow-up. Intravitreal methotrexate is a safe, effective and flexible treatment for PCNSL patients with intraocular involvement. Keratopathy is the most common adverse effect and can be controlled by reducing the injection frequency.
机译：已证明玻璃手枪甲氨蝶呤是一种有效的培养物淋巴瘤治疗方法。然而，在大多数情况下，角膜病发生在治疗期间的主要副作用。本研究的目的是用眼内参与描述原发性中枢神经系统淋巴瘤（PCNSL）的特征，并试图降低含有玻璃氨酸甲氨蝶呤引起的角抗病变的发生率。综述了22例PCNSL患者的医疗记录（33只眼）。患者分为两组。 A组（22只眼睛）接受了诱导巩固 - 维护方案，其剂量由400μg/ 0.1？ml的剂量为前四周两次，每周八周，然后每月九个月。系统性状况差的患者被分配给B组（8只眼），在上述治疗方案上开始，当达到眼部缓解时直接转换为每月注射（9？月）。模糊的视力（31％）和漂浮物（25％）是常见的呈现症状。伏特膜炎是最常见的临床标志，并在B-Ultrasound检查中存在于29只眼中（90％）。诊断由25g-pars plana玻璃体切除术进行，大多数诊断弥漫性大B细胞淋巴瘤。在甲氨蝶呤注射8.2（SD？= 4.6）后达到眼部缓解。从Logmar 0.65至0.3改善平均Va（视觉敏锐度）（p？= 0.002）。在平均8.2（SDα= 2.3）注射后，在21只眼睛（66％）中观察到角膜外疗法。由于注射频率降低，角膜athathy的发生率从86.4％（a）至25.0％（b）中，在随访期间没有眼部复发。玻璃手枪甲醇甲酸甲酸酯是针对眼内参与的PCNSL患者安全，有效和灵活的治疗方法。角膜athathy是最常见的不利影响，可以通过降低注射频率来控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号